Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | May 31, 2024
Distillery Therapeutics

Controlling SPHK1 and SPHK2 activity for heart failure

BioCentury | Aug 29, 2019
Distillery Therapeutics

SPHK1 in T cells identified as melanoma target

BioCentury | Feb 22, 2019
Targets & Mechanisms

Expansion into TNBC

How RNA-binding small molecules could sensitize TNBC to targeted therapies
BioCentury | May 23, 2018
Distillery Therapeutics

Neurology

BioCentury | Jun 19, 2014
Distillery Therapeutics

Indication: Hematology

BioCentury | Nov 11, 2013
Emerging Company Profile

SphynKx: Solving the S1P riddle

SphynKx developing modulators of endogenous S1P to treat fibrosis
BioCentury | Oct 4, 2012
Cover Story

Slipping past P glycoprotein

BioCentury | Jun 2, 2011
Distillery Therapeutics

Indication: Cancer

BioCentury | May 26, 2011
Distillery Therapeutics

Indication: Autoimmune disease

Items per page:
1 - 10 of 16